MRAI.OQXMarpai, INC
10-Q: Marpai Inc. Reports Q1 2025 Results, Revenue Declines Amid Strategic Review
Sentiment:
Quarterly Report
Marpai Inc. reports a decrease in revenue for Q1 2025, alongside an ongoing strategic review to maximize shareholder value and address liquidity concerns.
Capital raiseThe company is seeking additional funding through equity or debt financing.On May 13, 2025, Marpai entered into a securities purchase agreement with accredited investors to issue 730,000 shares at $1.00 per share.
Worse than expectedThe company's revenue decreased by 26.6% year-over-year, indicating a decline in business performance.Management has expressed substantial doubt about the company's ability to continue as a going concern, suggesting significant financial challenges.
Summary
- Marpai Inc. reported a net loss of $3.1 million for the three months ended March 31, 2025, compared to a net loss of $4.3 million for the same period in 2024.
- Revenue decreased by 26.6% to $5.4 million, primarily due to customer turnover.
- The company is exploring strategic alternatives, including a potential sale or merger, to maximize shareholder value.
- Marpai has a negative working capital of $6.9 million and an accumulated deficit of $101.9 million as of March 31, 2025.
- Management has expressed substantial doubt about the company's ability to continue as a going concern within the next twelve months without additional capital.
- The company is seeking additional funding through equity or debt financing.
- Operating expenses decreased due to cost-cutting measures and strategic realignments.
- The company issued 730,000 shares of common stock in a private placement on May 13, 2025, at $1.00 per share.
Sentiment
Score: 3
Explanation: The document presents a concerning financial situation with declining revenue, liquidity issues, and doubts about the company's ability to continue as a going concern. While there are some positive aspects like reduced losses and cost-cutting measures, the overall outlook is negative.
Positives
- The net loss decreased from $4.3 million in Q1 2024 to $3.1 million in Q1 2025.
- Operating expenses decreased due to cost-cutting measures and strategic realignments.
- Cash provided by investing activities was $500 thousand due to the sale of a business unit.
- The company is actively seeking additional funding through equity or debt financing.
Negatives
- Revenue decreased by 26.6% year-over-year, primarily due to customer turnover.
- The company has a negative working capital of $6.9 million and an accumulated deficit of $101.9 million.
- Management has expressed substantial doubt about the company's ability to continue as a going concern.
- Interest expense increased by $421 thousand to $819 thousand due to debt to JGB Collateral LLC.
Risks
- The company's ability to continue as a going concern is uncertain without additional capital.
- Customer turnover is negatively impacting revenue.
- The strategic review process may be costly and disruptive.
- The company's revenues are concentrated with a few major customers, and the loss of these customers could significantly decrease revenue.
- The company is subject to fluctuations due to changes in the exchange rate of the New Israeli Shekel (NIS).
Future Outlook
The company is exploring strategic alternatives to maximize shareholder value and is seeking additional funding through equity or debt financing. Management has expressed substantial doubt about the company's ability to continue as a going concern without additional capital.
Management Comments
- Based on our current financial condition, our Board of Directors (the Board), supported by our management team, is considering exploring strategic alternatives focused on maximizing shareholder value.
- The market is evolving, and we are adapting our approach to better serve our customers needs.
- While we have seen some customer turnover, we are confident that our new initiatives will lead to long-term revenue growth.
Industry Context
The healthcare administration and TPA market is competitive, with companies vying to provide cost-effective and technologically advanced solutions for self-insured employers. Marpai's strategic review suggests a response to market pressures and a need to adapt its business model.
Comparison to Industry Standards
- It's difficult to directly compare Marpai's results to industry standards without knowing the specific client mix and service offerings.
- Companies like UnitedHealth Group (Optum), Anthem (Elevance Health), and Aetna (CVS Health) have large TPA businesses, but they are much larger and more diversified.
- Smaller, specialized TPAs like Benefitfocus or Accolade might be more relevant comparables, but their financial disclosures may not be directly comparable.
- The revenue decline and liquidity concerns suggest Marpai is underperforming compared to some of its peers.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer | NA | Dallas Scrip | June 2, 2025 | Appointment |
Related Party Transactions
- In January 2024 and March 2024, the company entered into securities purchase agreements with an entity controlled by the Chief Executive Officer, various directors, and certain executives.
Stakeholder Impact
- Shareholders face uncertainty due to the company's strategic review and liquidity concerns.
- Employees may be affected by potential cost-cutting measures or restructuring.
- Customers may experience changes in service as the company adapts its approach.
- Creditors face increased risk due to the company's financial challenges.
Next Steps
- The company will continue to explore strategic alternatives.
- Management will seek additional funding through equity or debt financing.
- The company will focus on adapting its approach to better serve customers and drive long-term revenue growth.
Key Dates
| Date | Description |
|---|---|
| March 2022 | Marpai Captive, Inc. was founded as a Delaware corporation. |
| May 31, 2023 | Shareholders approved increasing the 2020 Global Incentive Plan by 500,000 shares. |
| January 16, 2024 | Entered into a securities purchase agreement with company insiders to issue 1,322,100 shares at $0.9201 per share. |
| February 5, 2024 | Entered into an Agreement of Sale of Future Receipts with Libertas Funding, LLC. |
| March 7, 2024 | Entered into a securities purchase agreement with HillCour to issue 910,000 shares at $1.65 per share. |
| April 15, 2024 | Entered into a Securities Purchase Agreement with JGB Collateral LLC to issue Senior Secured Convertible Debentures due April 15, 2027. |
| May 6, 2024 | Shareholders approved the 2024 Global Incentive Plan with 2,227,910 shares of common stock initially issuable. |
| May 24, 2024 | Informed Nasdaq of intention to withdraw from hearings and transition to OTCQX. |
| May 29, 2024 | Common stock suspended from trading on Nasdaq and commenced trading on OTCQX. |
| June 21, 2024 | Elected not to redeem an additional $5 million of the Debentures with JGB. |
| August 28, 2024 | Entered into a securities purchase agreement with two investors to issue 2,702,702 shares at $0.481 per share. |
| December 5, 2024 | Entered into a Securities Purchase Agreement with four investors to issue 621,194 shares at $1.13 per share. |
| December 30, 2024 | Entered into amendments to the Purchase Agreement and the Debentures with the Purchasers and the Agent. |
| January 17, 2025 | Received proceeds of $3.0 million from an additional investment by JGB that had been held in escrow. |
| January 28, 2025 | The compensation committee of the Board granted a director RSU award pursuant to which the holder has the right to receive an aggregate of 600,000 shares of our common stock in connection with the holder being a personal guarantor on new financing. |
| March 7, 2025 | The compensation committee of the Board granted various employees RSU awards, under which the holders have the right to receive an aggregate of 82,000 shares of our common stock. |
| May 13, 2025 | Entered into a securities purchase agreement with accredited investors to issue 730,000 shares at $1.00 per share. |
| May 13, 2025 | Board of Directors appointed Dallas Scrip as Chief Operating Officer, effective June 2, 2025. |
| May 14, 2025 | Expected closing date for the private placement offering of 730,000 shares. |
Keywords
financial results, strategic review, going concern, revenue decline, net loss, capital raise, Marpai, healthcare, TPA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.